Oppenheimer raised the firm’s price target on Eloxx Pharmaceuticals to $55 from $50 and keeps an Outperform rating on the shares. Eloxx recently updated ELX-02 Phase 2 data for Alport syndrome with nonsense mutations, and ELX-02’s safety and tolerability profile was in line with previous trials, the analyst tells investors in a research note. The 3-month follow-up data is expected in Q3 and Eloxx is preparing for regulatory meetings in Q4, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELOX:
- Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
- Eloxx Pharmaceuticals announces publication on its TURBO-ZM platform
- Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
- Eloxx Pharmaceuticals KOL even discussed Phase 2 results of ELX-02
- Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome